Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
806
datasets available to search
ShareScore release 0.9.0
Dataset results
806 results for “Cancer Vaccine”
Impact of Pharmacist-led Educational Intervention on Pneumococcal Vaccination Rates in Cancer Patients
ClinicalTrials.gov study NCT05229081. IPD Sharing: YES. Countries: 1. Publications: 5.
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
ClinicalTrials.gov study NCT03946358. IPD Sharing: NO. Countries: 1. Publications: 5.
Autologous OC-DC Vaccine in Ovarian Cancer
ClinicalTrials.gov study NCT01132014. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer
ClinicalTrials.gov study NCT03645148. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Increasing Breast, Cervical, and Colorectal Cancer Screening and HPV Vaccination Among Underserved Texans
ClinicalTrials.gov study NCT04638010. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine
ClinicalTrials.gov study NCT02178670. IPD Sharing: Not stated. Countries: 1. Publications: 1.
XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer
ClinicalTrials.gov study NCT07114666. IPD Sharing: NO. Countries: 1. Publications: 1.
Data from: Knowledge, attitudes, and practices among Indonesian urban communities regarding HPV infection, cervical cancer, and HPV vaccination
Open the record for dataset details and reuse information.
Adverse drug reactions to the three doses of the SARS-COV-2 mRNA-1273 vaccine in a cohort of cancer patients of a tertiary hospital
<p><strong>Introduction:</strong> SARS-CoV-2 vaccines efficacy and safety have been tested in phase 3 studies in which cancer patients were not included or underrepresented. Information is scarce regarding safety in this population. </p> <p><strong>Methods:</strong> The objective of this study is to evaluate the safety profile of the mRNA-1273 vaccine across cancer patients and its relationship to patients' demographics. This cross sectional study included patients 18-years or older with solid malignancies receiving active treatment in our hospital who had received the three dose schedule of the mRNA9 1273 vaccine and whose side effects after each dose were recorded. Patient electronic medical records were reviewed retrospectively to collect tha available information in 2021. Patients with documented previous infection by SARS-Cov-2 were excluded from the study.</p> <p><strong>Results:</strong> 93 patients met inclusion criteria. Local adverse drug reactions (ADRs) were reported more frequently after the first and second dose than after the third (41.9%, 43% and 31.1% of the patients respectively), while systemic ADRs were reported less frequently after the first and second dose than after the third (16.1%, 34.4% and 52.6% of the patients respectively). We found a statistically significant association between sex and systemic ADRs after the third dose. Cochran-Armitage test showed a statistically significant linear trend, p = 0.012, with higher ECOG score associated with a lower proportion of patients suffering from systemic side effects. A logistic regression showed that females had 5.79 times higher odds to exhibit systemic ADRs after the third dose (p=0.01) compared to males. Increasing age was associated with a decreased likelihood of exhibiting ADRs (p=0.016).</p> <p><strong>Conclusion:</strong> mRNA-1273 vaccine shows a tolerable safety profile. The likelihood of ADRs appears to be associated with gender and age. Its association with ECOG scores is less evident. Further studies are needed to elucidate this data in cancer patients.<span></span></p>
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
ClinicalTrials.gov study NCT05232851. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
ClinicalTrials.gov study NCT00305760. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer
ClinicalTrials.gov study NCT05996523. IPD Sharing: YES. Countries: 1. Publications: 0.
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
ClinicalTrials.gov study NCT03012100. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT05242965. IPD Sharing: NO. Countries: 1. Publications: 0.
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
ClinicalTrials.gov study NCT00112957. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer
ClinicalTrials.gov study NCT00082641. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
ClinicalTrials.gov study NCT00266110. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma
ClinicalTrials.gov study NCT00671554. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00019929. IPD Sharing: Not stated. Countries: 1. Publications: 0.
AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer
ClinicalTrials.gov study NCT03371485. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.